Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$88.74 USD

88.74
1,093,175

+4.62 (5.49%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (214 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

PDCO vs. MMSI: Which Stock Is the Better Value Option?

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Masimo's (MASI) Launch to Serve the Personalized Hearables Market

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Patterson Companies (PDCO) Q4 Earnings Beat, Sales Hurt by FX

Patterson Companies' (PDCO) fiscal fourth-quarter 2023 results reflect robust improvement in Dental Equipment sales, Value-added services and Animal Health segment.

Here's Why You Should Retain Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD) owing to strength in Omnipod 5 and its focus on market expansion.

QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod

QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering

Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.

Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe

Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.

3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

PacBio's (PACB) New Tie-Up to Boost Rare Disease Research

PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.

Quest Diagnostics (DGX) Partners to Offer New Testing Service

Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.

Here's Why You Should Buy Boston Scientific (BSX) Stock

Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.

What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?

The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.

Hologic (HOLX) Gains From Core Businesses' Growth, Innovation

Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care

Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.